Cytospire Therapeutics

London-based biotech startup Cytospire Therapeutics has successfully closed an oversubscribed £61 million ($83 million) Series A financing round led by 4BIO Capital.

Summary of transaction details:

• Value: £61 million ($83 million)
• Sector: Healthcare & Biotech / Oncology
• Advisor: Not disclosed
• Key Entities: Target: Cytospire Therapeutics; Lead Investor: 4BIO Capital; Participating Investors: Servier Ventures, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan, Pathway Bioventures, British Business Bank (£12m); Key Executives: Natalie Mount (CEO), Owen Smith (Partner, 4BIO Capital)
• Location: London, UK

Note: Founded in 2023, Cytospire is developing a pioneering portfolio of "pan-gamma delta T cell engagers"—a next-generation cancer immunotherapy designed to direct the body's immune cells to attack diseased cells more safely and effectively than conventional CD3 engagers. This £61m capital injection, backed by a massive syndicate of specialist life sciences investors, will advance Cytospire's pipeline through IND-enabling preclinical studies and GMP manufacturing. Specifically, it will fund the first-in-human clinical study of its lead programme, CYT X300, which is being evaluated as a treatment for EGFR-positive solid tumours, including colorectal, head and neck, and non-small cell lung cancers.